ASXL1 Mutations Predict Inferior Molecular Response to Nilotinib Treatment in Newly Diagnosed Patients with Chronic Myeloid Leukemia in Chronic Phase

Ernst T, Schoenfeld L, Rinke J, Hinze A, Nagel SN, Schaefer V, Schenk T, Fabisch C, Bruemmendorf TH, Burchert A, Le Coutre P, Krause S, Saussele S, Safizadeh F, Pfirrmann M, Hochhaus A (2022)

Publication Type: Conference contribution

Publication year: 2022

Journal

Blood American Society of Hematology

Publisher: AMER SOC HEMATOLOGY

City/Town: WASHINGTON

Conference Proceedings Title: BLOOD

Event location: New Orleans, LA

DOI: 10.1182/blood-2022-165041

Authors with CRIS profile

Stefan Krause Department of Medicine 5 – Haematology and Oncology

Involved external institutions

Universitätsklinikum Jena DE Germany (DE) Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen DE Germany (DE) Universitätsklinikum Gießen und Marburg (UKGM) DE Germany (DE) Charité - Universitätsmedizin Berlin DE Germany (DE) Ruprecht-Karls-Universität Heidelberg DE Germany (DE) Ludwig-Maximilians-Universität (LMU) DE Germany (DE)

How to cite

APA:

Ernst, T., Schoenfeld, L., Rinke, J., Hinze, A., Nagel, S.N., Schaefer, V.,... Hochhaus, A. (2022). ASXL1 Mutations Predict Inferior Molecular Response to Nilotinib Treatment in Newly Diagnosed Patients with Chronic Myeloid Leukemia in Chronic Phase. In BLOOD. New Orleans, LA: WASHINGTON: AMER SOC HEMATOLOGY.

MLA:

Ernst, Thomas, et al. "ASXL1 Mutations Predict Inferior Molecular Response to Nilotinib Treatment in Newly Diagnosed Patients with Chronic Myeloid Leukemia in Chronic Phase." Proceedings of the 64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), New Orleans, LA WASHINGTON: AMER SOC HEMATOLOGY, 2022.

BibTeX: Download